Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JSKN003 in advanced solid tumors
NCT05744427Phase 2Active, not recruiting
- Sponsor
- Alphamab Oncology
- Start
- Mar 2023
- Primary completion
- Jul 2026
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label trial of anbenitamab repodatecan in solid tumor (8 arms), sponsored by Alphamab Oncology. Primary endpoints: Dose-Limiting Toxicity at 21 days, Maximum Tolerated Dose at 12 months and 2 more. Started Mar 2023; status: active, not recruiting.
02
Drugs
anbenitamab repodatecan
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05744427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05744427.